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What does this work add to what is already known? 
This QUiPP app is the only decision-support tool for risk assessment of preterm birth in high-risk 
women.  This extensive validation of the new algorithms which use quantitative fetal fibronectin, 
cervical length or both tests combined,  provides crucial evidence for the popular app.    
 
What are the clinical implications of this work? 
Use of a such reliable tool in preterm surveillance clinics can assist in explanation of risk to women, 
facilitates complex management decisions and can help avoid unnecessary interventions. 
 
  





Accurate mid-pregnancy prediction of spontaneous preterm birth (sPTB) is essential to ensure 
appropriate surveillance of high-risk women.  Advancing the QUiPP prototype, QUiPP 2 aimed to 
provide individualised risk of delivery based on cervical length, quantitative fetal fibronectin (qfFN), 
or both tests combined, taking into account further risk factors, such as multiple pregnancy.   
Validation of the QUiPP 2 predictive models using a distinct dataset aims to confirm the accuracy 
and transportability of QUiPP overall and within certain clinically relevant timeframes. 
Methods 
This was a prospective secondary analysis of data from 13 UK preterm birth clinics. A total of 1803 
(3878 visits) women were included in the training set and 904 women (1400 visits) in the validation 
set. Survival analysis was used to identify the significant predictors of sPTB and parametric 
structures for survival models were compared and the best selected.  The estimated overall 
probability of delivery before six clinically important timepoints (30, 34, 37 weeks of pregnancy and 
within 1, 2 and 4 weeks of testing) was calculated for each woman and analysed as a predictive test 
for the actual occurrence of each event. This allowed receiver–operating characteristics (ROC) curves 
to be plotted, and areas under the curve (AUC) calculated.  Calibration was performed to measure 
the agreement between expected and actual outcomes. 
Results  
All algorithms demonstrated high accuracy; AUCs between 0.75 and 0.90 for the use of qfFN and 
cervical length combined, 0.68 and 0.90 for qfFN and 0.71 and 0.87 for cervical length. The 
differences between the three algorithms were not statistically significant. Calibration confirmed no 
significant differences between expected and observed rates of sPTB within 4 weeks and slight over-
estimation of risk with the use of cervical length measurement between 22-25+6 weeks’ gestation. 
Conclusion 
QUiPP app version 2 is a highly accurate prediction tool for prematurity, based on a unique 
combination of biomarkers, symptoms and statistical algorithm.  It can reliably be used in the 
context of discussing risk. Whilst further work is required to determine its role in identifying women 
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requiring prophylactic interventions, it is a reliable and convenient screening tool for planning 
follow-up or hospitalisation for high risk women. 
 
  




Premature birth (PTB) is a major determinant of lifelong health, and prevention of PTB of 
spontaneous onset is a key priority for service providers1.  Cervical length (CL) and quantitative fetal 
fibronectin (qfFN) can assist in identification of those most at risk2,3, but their clinical utility may be 
limited by implementing treatments around a binary threshold which categorises women into one of 
high risk or low risk, without the appreciation that risk is a continuous variable4.  Predictive 
modelling was incorporated into a decision-support tool in 2015 which provided an individualised 
risk of delivery within pre-specified timeframes for women based on use of CL and qfFN in 
combination. (https://quipp.org/)5.   The prototype was installed on over 1,000 devices in 51 
countries and our qualitative work suggested the app is a popular solution for communicating 
preterm birth risk with women. 6,7 
 
To enhance the accuracy and usability of the first version of the QUiPP app, we developed improved 
predictive models based on a larger dataset.  For the convenience of clinicians in a both 
symptomatic and high-risk asymptomatic settings, the second version of the QUiPP app aimed to 
enable prediction based on qfFN and CL either alone or in combination, rather than requiring the 
results from both tests (i.e. six different algorithms).   The inclusion of multiple pregnancies in the 
new models intended to enable prediction of spontaneous PTB (sPTB) in twin pregnancies using 
QUiPP rates.  This is important because 50% of twins deliver preterm and multiple pregnancy rates 
are rising due to increased maternal age and assisted conception procedures 8. The three algorithms 
for asymptomatic women were then validated on a separate dataset of high-risk asymptomatic 
women.  In this paper we report the validation methods for development of the three asymptomatic 
QUiPP v.2 prediction models and their accuracy in estimating risk of sPTB within 4 weeks of testing 
and of testing between 22+0 and 25+6 weeks’ gestation. These scenarios were chosen because they 
are likely to be useful contexts for managing and communicating risk for asymptomatic high-risk 
women.  We are not recommending a particular cut-off or threshold to guide interventions in this 
paper because the app produces probabilities of delivery, which need to be interpreted in light of 
their clinical context.  Development and validation of prediction models for use in the care of 
symptomatic women are described by this group’s related paper (“Development and validation of 
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prediction models for QUIPP v.2, a tool for predicting preterm birth in symptomatic women” also 








The QUiPP v.2 predictive models were generated by analysis using data collected from the 
prospective cohorts EQUIPP (REC number 10/H0806/68), INSIGHT (REC number 13/LO/0393) and 
POPPY studies between October 2010 and May 2017.  Thirty five percent of the women (n=624) in 
the training dataset were also in the training set for the first version of the QUiPP app5.  Since the 
models were destined for an updated version of a decision-making app, inclusion of all available 
data aimed to enhance predictive accuracy and there was no statistical or clinical reason to exclude 
the earlier data. The validation set included later participants from EQUIPP and INSIGHT studies 
between May 2017 and February 2019.  This allowed us to test the models’ performance on a new 
dataset and test transportability, given variations in the historical period but with a “plausible-
related” sample (temporal validation)9,10. 
 
All women were asymptomatic and enrolled from 13 high-risk preterm surveillance clinics across the 
UK.  Women were offered longitudinal qfFN testing using the quantitative rapid fFN analyzer 
(Hologic, Marlborough, MA, USA) every 2–4 weeks and/or transvaginal ultrasound CL measurement 
between 18+0 and 36+6 weeks’ gestation.  All women had at least one of the following risk factors for 
sPTB: previous preterm birth or prelabour rupture of membranes (PPROM ) < 37 weeks,  previous 
late miscarriage (16+0 -23+6 weeks), previous  cervical surgery (e.g. LLETZ or cone biopsy) or twin 
pregnancy. Gestational age was confirmed with standard first trimester ultrasound scans.  Each 
woman had cervical length measurement and/or qfFn measurement performed at the screening 
visit.  The qfFN sample collection and transvaginal ultrasonic cervical length measurement were 
performed as previously described11 .  As per clinical protocols, the shortest cervical length 
measurement of three was used for this analysis. Women with a blood-stained swab or a history of 
vaginal douching or sexual intercourse within the last 24h were excluded from the study due to 
known interference with qfFN measurement. Participants’ demographic characteristics, risk factors 
and obstetric history were entered into a secure online database (www.medscinet.net/PTBstudies). 
Women were managed as per unit protocols, with ultrasound-indicated cerclage offered if the 
shortest CL was measured as <25 mm prior to 24+0 week’s gestation. Women with a cervix of <25 
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mm may also have been offered alternative treatments (vaginal progesterone or Arabin pessary) as 
part of relevant randomised-controlled trials (SuPPoRT, STOPPIT-2)12,13. 
 
 
The primary studies were approved by South East London Research Ethics Committee (EQUIPP and 
POPPY) and City & East Research Ethics Committee (INSIGHT) and the local research ethics 




The QUIPP v.2 predictive models were created using CL and qffN data, CL alone and qfFN alone from 
the asymptomatic high-risk datasets. Statistical analysis was performed with Stata software 
(StataCorp, College Station, Texas). 
 
Model generation 
In developing the predictive models, there were two priorities:  
1. We had a relatively small data set of high-quality information.  We needed to make full use 
of all available data; every CL measurement or qfFN test carried out (according to Hologic’s 
instructions), and for which the ultimate pregnancy outcome was known.  
2. We aimed to produce a method of predicting prematurity that was simple enough to be 
programmed into a spreadsheet or a smartphone application; and accurate enough to aid 
clinical decision-making. 
 
We made an early decision not to use logistic regression.  This would have resulted in separate 
models for each endpoint; possibly producing inconsistent results.  Instead, we opted to use survival 
analysis, so that a single, more powerful, model could estimate likelihood of delivery at any 
gestation.  The modelling process is described in detail in the supplementary file: Statistical Methods 
for Creation of App Algorithms. 





The validation set comprised high-risk asymptomatic women enrolled in the EQUIPP and INSIGHT 
studies up to February 2019 where outcomes had been collected since creation of the prediction 
models using the training set in May 2017.  Multiple tests for individual women were included in the 
validation set because if a woman is tested on multiple occasions we wish to know the performance 
of every one of those test results. All the results included were taken at clinically appropriate times, 
so the results are all relevant to the validation process, and it is appropriate to include them.  
Selecting one episode per women would artificially reduce the dataset; and might introduce bias due 
to the selection process. Deliveries were classified as iatrogenic if labour was induced or a caesarean 
section was pre-labour, where membranes were intact. Induction of labour or CS following PPROM 
were treated as sPTB. For calculation of sPTB rates, if the birth was preterm (e.g. before 37 weeks) 
but iatrogenic, this data was counted as missing rather than excluded altogether since the data may 
be included within other outcomes (e.g. delivered within 7 days).  
 
To estimate how well the QUiPP app discriminates between those who do, and those who do not, go 
on to have sPTB, the overall probability of delivery before six clinically important points in time (30, 
34, 37 weeks of pregnancy and within 1, 2 and 4 weeks of testing) was calculated for each test event  
and analysed as a predictive test for the actual occurrence of each event. This allowed receiver–
operating characteristics (ROC) curves to be plotted, and areas under the curve (AUC) calculated.   
 
With preterm birth surveillance advisable for high-risk women2, 1 we estimated that a four weekly 
interval was most likely to be feasible for most services and therefore we focused on achieving a 
high level of confidence in the algorithms  ability to predict delivery within 4 weeks. To provide an 
accurate estimate of the uncertainty associated with all three algorithms’ AUCs (for probability of 
sPTB within four weeks) bootstrapped confidence intervals were calculated.  Bootstrapping allows 
for clustering by participant, in this case caused by repeated visits. To obtain an estimate of the 
bootstrap distribution 1,000 replications of the non-parametric resampling method were performed.  
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A sampling bias correction with acceleration was employed to allow for the fact that this data is not 
normally distributed.14   
 
 
Calibration is another important method for measuring performance of predictive models and refers 
to the agreement between observed outcomes and predictions 15. a calibration-in-the-large 
approach was used to compare the mean probability of delivery within 4 weeks with event rate and 
calibration-in-the-small to compare event rates with probabilities of <1%, 1-4.9%, 5-9.9% and > 10% 
delivery within 4 weeks.  Calibration is essentially a check of accuracy.  The aim of calibration-in-the-
large is to check that the overall number of events actually observed is consistent with then number 
predicted.  The aim of calibration-in-the-small is to check that groups of subjects with different 
predicted event rates do indeed have different actual event rates, as predicted 
 
The performance of the app around 24 week’s gestation is relevant to clinical decision-making 
regarding communicating risk and discharging women from preterm surveillance clinics, particularly 
at peri-viable gestations.  For tests carried out between 22+0 and 25+6 weeks’ gestation, the QUIPP 
v.2 performance in prediction of sPTB <30/34/37 weeks’ gestation for each test group (CL alone, 
qfFN alone and both tests combined), was evaluated using ROC curves.  When tests were repeated 
within this window, the first test result was used.  Calibration-in-the-large and calibration-in-the-
small was also performed to compare predicted with actual outcomes.  For qfFN, CL and qfFN+CL 
taken between 22+0 and 25+6 weeks’ gestation, probabilities of delivery before 34 and 37 weeks were 
compared with actual event rates and their binomial exact 95% confidence intervals. 
 





Overall, 2303 asymptomatic women at high risk of sPTB from the EQUIPP, POPPY and INSIGHT 
prospective cohorts studies were selected from the trial database.  Visits with incomplete qfFN/CL 
data (n=175), blood-stained swabs (n=85), invalid qfFNs (n=2), or sexual intercourse within 48 hours 
(n=233) were excluded from analysis. Triplets and one set of quads were excluded as prevalence of 
these higher order multiple pregnancies was too low to be useful but 150 sets of twins were 
included (with gestation of delivery of the first baby 1 used in the analysis)  Following exclusions, CL 
and qfFN measurements from 1803 women at 3878 visits were analysed (Figure 1). This dataset 
including 288 spontaneous and 165 iatrogenic preterm deliveries.   All measurements of qfFN and CL 
were taken between 18+0 and 36+6 weeks.  The baseline characteristics for these women are 
described in Table 1.  
 
Prediction models were created for use in three test groups (risk factors with CL alone, risk factors 
with qfFN alone and risk factors with CL and qfFN combined) from the training set.  Parametric 
survival analysis with time-updated covariates was used to get the maximum information from the 
available data. For all three models the loglogistic 1 structure was the most accurate, using time of 
conception as time zero, even though women were observed only from time of test.  For all three 
models, multiple pregnancy, previous sPTB and previous late miscarriage were required in the 
model.  Other potential predictors (body mass index, smoking, ethnicity, and previous cervical 
surgery) were excluded as not significant in a multiple regression model.  Smoothed hazard 
estimates using Cox regression suggest time-dependent risk factors for some variables including, 
qfFN, cervical surgery and late miscarriage.  For example, Figure 2 demonstrates the increasing risk 
of delivery with higher levels of qfFN and how even with low levels of qfFN, the hazard increases as 
you get beyond 200 days (28 weeks’ gestation).  This means that at earlier gestations risk is slightly 
over-estimated compared to a slight under-estimation of risk at late preterm gestations.  Given that 
early preterm deliveries are most important and difficult to predict, this statistic anomaly actually 
incurs additional safety in the app, and a more complex statistical model for the app has not been 
sought. 





For the validation set 1457 asymptomatic, high risk women with singleton or twin pregnancies were 
identified during the time period, with over 2211 visits.  Exclusions were comparable with the 
training set and described in Figure 1.  The complete validation dataset then included 1400 visits and 
904 women (none of whom were included in the validation set for the first QUiPP algorithms).   
 
The baseline demographics, risk factors and outcomes of the validation set were compared with the 
training set in Table 1. The validation set contains a significantly higher proportion of black women, 
and women with a previous sPTB or PPROM and significantly fewer Asian women and twin 
pregnancies. Whilst both datasets included women from across the UK, a greater contribution from 
INSIGHT recruits (70% of whom were recruited in an inner-city London hospital) in the later 
validation dataset is likely to account for these contrasts. This is an intended consequence of the 
temporal validation method which aims to assess the generalizability of the predictive models in 
different populations. 
 
ROC curves for the qfFN, CL and qfFN/CL algorithms, based on all women in the dataset are shown 
(Figure 3).  All algorithms demonstrated good accuracy with areas under the curve (AUC) between 
0.75 and 0.90 for the use of qfFN and CL combined, between 0.68 and 0.90 for qfFN and between 
0.71 and 0.87 for CL. There were insufficient event rates for prediction within one and two weeks in 
this asymptomatic population to be useful. P values and confidence intervals for overall prediction 
have not been reported because no correction was made for repeated tests for most AUCs.  
Bootstrapped confidence intervals were calculated for delivery within 4 weeks of test were narrow 
supporting the models’ reliability and no significant difference between the three algorithms (qfFN, 
CL, combined qfFN/CL) (Table 2).   
 
Calibration for probability of delivery within 4 weeks included 1095 observations for qfFN alone, 988 
observations for CL alone and 694 for combined use of qfFN and CL.  Women were excluded if 
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spontaneous delivery before 4 weeks could not be determined because of iatrogenic delivery within 
this timeframe.  Tables 3 and 4 group women according to results on the QUiPP app.  Calibration 
demonstrated no significant difference between the event rates and the predicted probabilities in 
any algorithm, confirming the QUiPP app’s reliability at estimating risk of delivery within 4 weeks. 
(Table 3). The qfFN algorithm in Table 3 demonstrates the app’s ability to segregate women 
according to true risk; a low (<1%) risk on the QUiPP app is associated with an event rate of only 
0.5%, while a high risk of delivery within 4 weeks (>10%) probability is associated with a 26% risk of 
delivery within 4 weeks, compared to a no information rate of 2.9%. There are similar findings for 
the other biomarkers and other endpoints.  
 
 
QUiPP v.2 predictive power at 22+0 to 25+6 weeks’ gestation was good (AUC 0.763 for delivery <34 
weeks and 0.746 for delivery <37 weeks using qfFN and CL) (Figure 4). For calibration at this 
gestation there were 1081 eligible observations for qfFN alone, 977 observations for CL alone and 
689 observations for qfFN and CL.  Event rates (sPTB < 34 and < 37 weeks) were similar to predicted 
rates of delivery using the qfFN algorithm for nearly all women.  For the CL and CL/qfFN algorithms, 
the addition of CL data appeared to lead to statistically significant over-estimation of QUiPP risk, 
with predicted delivery rates above the upper confidence interval for actual delivery rates, 
particularly at higher risks (Table 4.) 
 




Created from data from over 1800 asymptomatic women, (three times the number used for creation 
of the prediction models used in first version of the QUiPP app) and validated on a significantly 
different population, this new version substantially increases the reliability and generalisability of 
QUiPP’s prediction. For the first time, the new QUiPP app provides clinicians with three accurate 
methods for predicting preterm birth in high-risk women: using qfFN, CL or both tests together.  
Whilst there were trends towards improved prediction with both tests, these were not significant.  
The new version of the QUiPP app also incorporates calculation of risk in women with a twin 
pregnancy due to the inclusion of a large number of twin pregnancies (n=150) in the models’ 
generation. Given uncertainties regarding the optimal management of twin pregnancies,16,17,18 
accurate identification of those most at risk of early preterm birth could help identify those most 
likely to benefit from intervention whilst reassuring the majority.  
 
In this paper we have directly evaluated the performance of the QUiPP app, as used in the setting of 
a preterm surveillance clinic.  This is timely since the NHS’ new Saving Babies’ Lives Care Bundle has 
made the provision of such clinics mandatory.1  The QUiPP app may be a reliable tool in the 
establishment of preterm birth prevention pathways. We have confirmed excellent accuracy (AUCs > 
0.87 for all three combinations of tests) for prediction of preterm birth within 4 weeks which is 
pertinent to clinicians planning serial follow up. Whilst the reported predictive performance are 
based on individual episodes, serial testing remains best practice1,2,  will enhance the accuracy of 
tests further and is likely to be desirable to women with previous difficult experiences.   The results 
from this study suggest that the app correctly predicts around half of visits with a < 1% risk of 
delivery within 4 weeks.  At such a low level of risk, monthly follow-up may be acceptable, whereas 
an prompter appointment is likely to be appropriate for women with higher calculated risks.   The 
models’ accurate discrimination of women with a higher (e.g. > 10% ) risk of delivery before 34 or 37 
weeks at 22+0 to 25+6 weeks’ gestation, means that QUiPP can reliably inform discussion of sPTB risk 
at the time women tend to be discharged from the specialist preterm clinic.   
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The app is a decision-making aid which we hope can make a valuable contributions to bespoke 
management plans,  but we intentionally avoided providing a single cut-of.  It is likely that a 
randomised-controlled trial design is required to address whether a specific QUiPP risk should 
prompt interventions such as cerclage or pessary. Furthermore, one of the key motivators for 
creating the app was that a single cut-off does not reflect the true utility of data across the risk range 
of variables such as cervical length and qfFN.  Reducing the app output back to a binary threshold 
would under-estimate the importance of the clinical context and the woman’s role in shared 
decision-making.  In the absence of interventional trial data, we are not suggesting  changing the 
approach for the majority of women at risk of preterm birth.  However, given the reliability of the 
app’s performance (Table 4), if at a peri-viable gestation a woman has a borderline CL but an overall 





Based on the results of our calibration, when QUiPP provides very low probabilities for preterm 
birth, event rates were consistently even lower providing a high level of reassurance to clinicians and 
women alike.   In fact, there was a degree of over-estimation of risk, which was significant for the CL 
algorithms.   It is possible that women with a short cervix did not deliver as soon as QUiPP predicted 
because these women received prophylactic interventions for sPTB, (e.g. cerclage, progesterone or 
Arabin pessary). However, this effect was significant for prediction at 22-25+6 weeks’ when half of 
the women would not be eligible for prophylactic interventions, so treatment paradox may not fully 
explain this effect.  Nevertheless, a degree of caution in the QUiPP app’s estimations is likely to be 
protective and desirable, as avoiding the consequences of false negative results is more important 
than avoiding false positive results in sPTB risk assessment. 
 
There were significant differences between our validation and training set which supports the QUiPP 
app’s generalizability.  In a vastly different population to either our training or validation set, 
cautious use of the QUiPP app is advised.  In the future, as new insights into the pathophysiology of 
preterm parturition are realised and additional biomarkers are identified and large preterm birth 
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cohorts allow identification of new significant variables for the prediction models, there is potential 
to incorporate additional data into future iterations of QUiPP to refine prediction further. 
 
  
The clinical impact of the QUiPP app for symptomatic women in terms of reducing inappropriate 
management of threatened preterm labour has been evaluated in a large randomized-controlled 
trial (EQUIPTT ISRCTN 17846337 due for publication late 2019).  Similar trials are required for the 
asymptomatic population.  
 
In conclusion, building on experiences and feedback from the first version, the second version of the 
QUiPP app provides enhanced usability and accuracy for risk assessment of high-risk women in 
preterm surveillance clinics.   In accommodating a number of risk factors for sPTB, it is the only tool 
that provides women with a bespoke preterm birth risk, and can provide significant reassurance to 
women and clinicians, as well as health resource savings by preventing inappropriate admissions and 
treatments.  Its rigorous validation and compliance with software application regulations (CE marked 
Sept 2017 MHRA Ref A015030) support its widespread clinical use within preterm birth surveillance 
protocols.  
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Figure 1: Eligibility flowchart for QUiPP 2 asymptomatic predictive model datasets 
Figure 2:Cox regression smoothed hazard estimates be gestation for different categories of 
quantitative fFN 
Figure 3: ROC curves demonstrating the overall prediction  values for  quantitative fetal fibronectin, 
cervical length and both tests combined using QUiPP app. ROC curves presented for delivery 
< 30, 34 and 37 weeks and within one week  from test. 
Figure 4: ROC curves for QUiPP prediction using quantitative fetal fibronectin, cervical length and 
both tests combined at 22+0-25+6 week's gestation 
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Table 1: Baseline Characteristics of asymptomatic women providing data for model generation and validation of the Quipp 
app algorithm datasets
Characteristic Training set 
(n=1803)
























0.18 (-0.23 to 0.59)
0.38 (-0.04 to 0.81)
Relative Risk
0.51 (0.37 to 0.71)*
1.90 (1.62 to 2.23)*

















0.67 (0.61 to 0.74)*
0.47 (0.40 to 0.55)*
0.97 (0.84 to 1.13)
0.88 (0.80 to 0.96)*
3.97 (2.42 to 6.54)*
Number of visits per 
woman (mean)
2.17 1.53 0.64 ( 0.54 to  0.73)*
Pregnancy Outcomes













-1.28 (-3.28 to  0.73)
0.99 (0.81 to 1.22)
1.08 (0.94 to 1.25)   
0.98 (0.93 to 1.03)
Data given as mean or n (%) and standard deviation
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Table 2: QUiPP app predictive accuracy of delivery within 4 weeks of testing
Area under the curve (AUC) (bootstrapped confidence intervals)Prediction 
timeframe fFN alone (m-1095) CL alone (n=988) fFN and CL (n-694)










This article is protected by copyright. All rights reserved.




Predicted event rate * Actual event rate 
x/n (%)
95% CI of actual 
event rate
<1% (561) 0.6% 0.5% (3) 0.1 to 1.6
1 to 4.9% (424) 2.0% 2.4% (10) 1.1 to 4.3
5 to 9.9% (57) 6.9% 8.8% (5) 2.9 to 19.3
>10% (53) 23.5% 26.4% (14) 15.3 to 40.3
All women 
(calibration in the large)




Predicted event rate * Actual event rate 
x/n (%)
95% CI of actual 
event rate
<1% (499) 0.5% 0.2% (1) 0.0 to 1.1
1 to 4.9% (354) 2.1% 1.9% (7) 0.8 to 4.0
5 to 9.9% (55) 7.0% 5.5% (3) 1.1  to 15.1
>10% (80) 24.6% 13.8% (11) 7.1 to 23.2
All women 
(calibration in the large)
3.4% 2.2% 1.4 to 3.4
fFN and CL (n=694)
Predicted probability
(calculated by QUiPP)
Predicted event rate * Actual event rate 
x/n (%)
95% CI of actual 
event rate
<1% (383) 0.4% 0.3% (1) 0.0 to 1.4
1 to 4.9% (204) 2.1% 1.5% (3) 0.3 to 4.2
5 to 9.9% (41) 6.7& 0.0% (0) 0.0 to 8.6
>10% (66) 24.1% 18.2% (12) 9.8 to 29.6
All women 
(calibration in the large)
3.6% 2.3% 1.3 to 3.7
* The predicted event rate is the average of the predicted probabilities, as calculated by the 
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Table 4: QUiPP app calibration results for tests performed between 22-25+6
fFN alone  (n=1081)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 3.5% 2.2% (9) 1.0 to 4.1
5-9.9% 6.9% 7.3% (33) 5.0 to 10.0
>10% 25.5% 20.2% (44) 15.1 to 26.1
Overall (calibration in the large) 9.3% 8.0% (86) 6.4 to 9.7
CL alone (n=977)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 3.5% 2.3%(5) 0.7 to 5.3
5-9.9% 7.3% 2.9% (10) 1.4 to 5.3
>10% 24.1% 14.2% (59) 11 to 18
Overall (calibration in the large) 13.6% 7.6% (74) 6.0 to 9.4
fFN and CL (n=689)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 3.8% 0.0% (0) 0.0 to 4.5
5-9.9% 7.5% 4.4% (11) 2.2 to 7.7
>10% 24.7% 13.7% (49) 10.3 to 17.7
Overall (calibration in the large) 16.0% 8.7%(60) 6.7 to 11.1
fFN alone (n=1020)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 4.5% 3.0% (2) 0.4 to 10.5
5-9.9% 7.2% 10.4% (41) 7.6 to 13.8
>10% 21.3% 23.3% (130) 19.8 to 27.0
Overall (calibration in the large) 14.8% 17.0% (173) 14.7 to 19.4
CL alone (n=935)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 3.4% 2.0% (1) 0.0 to 10.5
5-9.9% 7.6% 6.3% (13) 3.4 to 10.5
>10% 26.0% 21.3% (144) 118.3 to 24.6
Overall (calibration in the large) 20.7% 16.9% (158) 14.6 to 19.5
fFN and CL (n=656)Predicted probability delivery 




Actual event rate 
x/n (%)
95% CI of actual 
event rate
1-4.9% 4.3% 0.0% (0) 0.0 to 30.1
5-9.9% 8.0% 3.0% (3) 0.6 to 8.5
>10% 27.3% 21.1% (115) 17.7 to 24.5
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Figure 1: Eligibility flowchart for QUiPP 2 asymptomatic predictive model datasets
Asymptomatic high-risk women with singleton or twin pregnancies recruited in EQUIPP, 
INSIGHT and POPPY studies
October 2010- May 2017 May 2017- February 2019
2303 women (4869 visits) 1457 women (2211 visits)
1803 women (3878 visits) 904 women (1400 visits)
Excluded visits:
• Visits < 18
+0
 weeks’ 




• Incomplete fFN/CL 
(175)
• Blood-stained swab 
(85)
• Sexual intercourse < 
24 hours (237)
• Major congenital 
malformations (5)
Excluded visits:
• Visits < 18
+0
 weeks’ 
gestation or > 36
+6 
(236)
• Incomplete fFN/CL 
(339)
• Blood-stained swab 
(35)
• Sexual intercourse < 
24 hours (97)
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Figure 3: ROC curves demonstrating the overall prediction  values for  quantitative fetal fibronectin, cervical length and both 
tests combined using QUiPP app. ROC curves presented for delivery < 30, 34 and 37 weeks and within one week  from test.
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Figure 4: ROC curves for QUiPP prediction using quantitative fetal fibronectin, cervical length and both tests combined at 
22+0-25+6 week's gestation
ROC showing prediction of delivery <34 
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